Cartesian Therapeutics doses first patient in phase 2 clinical trial of Descartes─08 to treat systematic lupus erythematosus

First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus

drugs.com - 03/Jul 04:07

GAITHERSBURG, Md., July 02, 2024. artesian Therapeutics, Inc. (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell...

First Patient Dosed in the MAD Part 2 Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

drugs.com - 26/Jun 19:06

CAMBRIDGE, Mass., June 26, 2024. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on transforming cardiometabolic...

Immunocore: Research Scientist - Autoimmune Diseases

pharmiweb.com - 25/Jun 10:06

GBP34000 - GBP40000 per year: Immunocore: Immunocore (NASDAQ: IMCR) is a pioneering, commercial-stage T cell receptor biotechnology company whose...

Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg

drugs.com - 02/Jul 04:07

DAEJEON, South Korea, July 2, 2024. PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public company developing...

Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study

zacks.com - 27/Jun 14:26

Beam Therapeutics (BEAM) doses the first patient in a phase I/II study, evaluating in vivo base editor BEAM-302 for treating alpha-1 antitrypsin...

University of Nebraska Medical Center enrolls patient for RenovoRx's pivotal phase III TIGeR─PaC trial

pharmabiz.com - 28/Jun 00:00

RenovoRx, Inc, a clinical─stage biopharmaceutical company developing novel precision oncology therapies based on a local drug─delivery platform,...

EG 427 receives US FDA clearance to initiate phase 1b/2a study of gene therapy, EG110A to treat NDO in spinal cord injury patients

pharmabiz.com - 26/Jun 00:00

EG 427, a biotechnology company leading the development of pinpoint DNA medicines for prevalent diseases in neurology based on its unique...

Synaptogenix gets US FDA authorization of IND application for clinical trial for Bryostatin─1 to treat multiple sclerosis

pharmabiz.com - 01/Jul 00:00

Synaptogenix, Inc., an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, announced that the Food & Drug...

PharmAust raises cash for anti-cancer study

aumanufacturing.com.au - 23/Jun 16:07

Clinical stage biotechnology company PharmAust has received commitments to raise $10 million via an institutional placement with directors and...

Imugene delivers first combo dose in bile tract cancer study

thewest.com.au - 24/Jun 08:20

Imugene has confirmed the delivery of its first “onCARlytics” combination therapy dose to a bile duct cancer patient in the initial phase of a...

Rubriques :